Abstract
We propose an additional intervention that would contribute to the control of the COVID-19 pandemic, offer more protection for people working in essential jobs, and help guide an eventual reopening of society. The intervention is based on: (1) testing every individual (2) repeatedly, and (3) isolation of infected individuals. We show here that at a sufficient rate of testing and isolation, the R0 of SARS-CoV-2 would be reduced well below 1.0, and the epidemic would collapse. The approach does not rely on strong and/or unrealistic assumptions about test accuracy, compliance to isolation, population structure or epidemiological parameters, and its success can be monitored in real time by measuring the change of the test positivity rate over time. In addition to the rate of compliance and false negatives, the required rate of testing is dependent on the design of the testing regime, with concurrent testing outperforming random sampling of individuals. Provided that results are reported rapidly, the test frequency required to suppress an epidemic is linear with respect to R0, to the infectious period, and to the fraction of susceptible individuals. Importantly, the testing regime would be effective at any level of prevalence, and additive to other interventions such as contact tracing and social distancing. It would also be robust to failure, as even in the case where the testing rate would be insufficient to collapse the epidemic, it would still reduce the number of infected individuals in the population, improving both public health and economic conditions. A mass-produced, disposable antigen or RNA test that could be used at home would be ideal, due to the optimal performance of concurrent tests that return immediate results.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
No external funding was used
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
No IRB approval was necessary
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
Data Availability
The paper is computational and therefore includes no new experimental data
